AU2015306108B2 - Medicament and apparatus for treating chronic kidney disease - Google Patents

Medicament and apparatus for treating chronic kidney disease Download PDF

Info

Publication number
AU2015306108B2
AU2015306108B2 AU2015306108A AU2015306108A AU2015306108B2 AU 2015306108 B2 AU2015306108 B2 AU 2015306108B2 AU 2015306108 A AU2015306108 A AU 2015306108A AU 2015306108 A AU2015306108 A AU 2015306108A AU 2015306108 B2 AU2015306108 B2 AU 2015306108B2
Authority
AU
Australia
Prior art keywords
bsp
blood
plasma
calcification
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015306108A
Other languages
English (en)
Other versions
AU2015306108A1 (en
Inventor
Franz Paul Armbruster
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immundiagnostik AG
Original Assignee
Immundiagnostik AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immundiagnostik AG filed Critical Immundiagnostik AG
Publication of AU2015306108A1 publication Critical patent/AU2015306108A1/en
Application granted granted Critical
Publication of AU2015306108B2 publication Critical patent/AU2015306108B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
AU2015306108A 2014-08-19 2015-08-19 Medicament and apparatus for treating chronic kidney disease Active AU2015306108B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102014111859 2014-08-19
DE102014111859.6 2014-08-19
PCT/EP2015/069098 WO2016026917A2 (en) 2014-08-19 2015-08-19 Medicament and apparatus for treating chronic kidney disease

Publications (2)

Publication Number Publication Date
AU2015306108A1 AU2015306108A1 (en) 2017-03-09
AU2015306108B2 true AU2015306108B2 (en) 2020-12-10

Family

ID=54014792

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015306108A Active AU2015306108B2 (en) 2014-08-19 2015-08-19 Medicament and apparatus for treating chronic kidney disease

Country Status (6)

Country Link
US (2) US10253092B2 (enExample)
EP (1) EP3182995B1 (enExample)
JP (2) JP6675383B2 (enExample)
AU (1) AU2015306108B2 (enExample)
CA (1) CA2958263C (enExample)
WO (1) WO2016026917A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2958263C (en) * 2014-08-19 2022-12-13 Immundiagnostik Ag Medicament and apparatus for treating chronic kidney disease
EP3924735A1 (en) 2019-02-15 2021-12-22 Immundiagnostik AG Rapid test for diagnosis of bacterial infections in neonates
EP4028418A1 (en) * 2019-09-14 2022-07-20 Immundiagnostik AG Medicinal preparation for treating fibrosis with anti bsp antibodies
WO2021226064A1 (en) * 2020-05-04 2021-11-11 University Of Louisville Research Foundation, Inc. Artificial intelligence-based systems and methods for dosing of pharmacologic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091379A1 (en) * 2001-06-13 2011-04-21 Armbruster Biotechnology Gmbh Method for treating tumors and their metastases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0337075A (ja) * 1989-07-04 1991-02-18 Baiteku Res:Kk 抗体固定担体、その製造方法およびその用途
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3329868B2 (ja) * 1992-09-30 2002-09-30 株式会社クラレ ペプチドおよびこれを担体上に固定化してなる吸着剤
CA2355228A1 (en) 1998-12-22 2000-06-29 University Of Virginia Patent Foundation Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
US7790853B2 (en) * 2001-06-13 2010-09-07 Franz Paul Armbruster Determination of bone-sialoprotein in bodily fluids for oncological problems
JP4177702B2 (ja) * 2003-04-28 2008-11-05 株式会社三重ティーエルオー 血液浄化用吸着材及びそれを用いたＩｇＡ腎症治療システム
WO2011000086A1 (en) 2009-07-03 2011-01-06 The Governors Of The University Of Alberta Method and apparatus for reducing serum phosphate in hemodialysis patients
EP2558177A1 (en) * 2010-04-15 2013-02-20 Fresenius Medical Care Holdings, Inc. Anticoagulant-free dialysis systems and methods
CA2958263C (en) * 2014-08-19 2022-12-13 Immundiagnostik Ag Medicament and apparatus for treating chronic kidney disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110091379A1 (en) * 2001-06-13 2011-04-21 Armbruster Biotechnology Gmbh Method for treating tumors and their metastases

Also Published As

Publication number Publication date
WO2016026917A2 (en) 2016-02-25
EP3182995B1 (en) 2019-11-27
CA2958263C (en) 2022-12-13
JP2020114823A (ja) 2020-07-30
AU2015306108A1 (en) 2017-03-09
US20170204172A1 (en) 2017-07-20
JP6968220B2 (ja) 2021-11-17
JP2017527553A (ja) 2017-09-21
WO2016026917A3 (en) 2016-06-09
JP6675383B2 (ja) 2020-04-01
US10947301B2 (en) 2021-03-16
US10253092B2 (en) 2019-04-09
CA2958263A1 (en) 2016-02-25
US20190177403A1 (en) 2019-06-13
EP3182995A2 (en) 2017-06-28

Similar Documents

Publication Publication Date Title
US10947301B2 (en) Method of treating extracellular tissue and vascular calcification and arteriosclerosis
Paloian et al. Osteopontin protects against high phosphate-induced nephrocalcinosis and vascular calcification
Milovanova et al. Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV (Systematic Rewiew and Meta-Analysis). Chronic Kidney Disease and renal Transplantation. Ed. by Manisha Sahay
RU2014106652A (ru) Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
JP2017533191A5 (enExample)
Messa et al. Behaviour of phosphate removal with different dialysis schedules
Chalmers Applied anatomy and physiology and the renal disease process
JP6910800B2 (ja) Ｇｄｆ１５調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
US20170312309A1 (en) Intradialytic administration of sodium thiosulfate
US20040247597A1 (en) Method of treating atherosclerosis and other inflammatory diseases
Checheriţă et al. Vascular calcifications in chronic kidney disease–clinical management
Chen et al. Cardiometabolic syndrome and vascular calcification
Bosch et al. Efficacy of lipid apheresis: definitions and influencing factors
Almafragi et al. Calciphylaxis in a cardiac patient without renal disease
JP2024536529A (ja) 全血のアフェレーシス
Kuhn et al. Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis
Abudayyeh et al. Myeloma, Amyloid, and Other Dysproteinemias
Sanders Dysproteinemias and amyloidosis
Mihaylov et al. Determining the levels of vitamin D and parathyroid hormone in patients on hemodialysis
Stalling Generation of an autoimmune model of THSD7A-associated membranous nephropathy in BALB/c mice
LIGHT-CHAIN 28 Myeloma, Amyloid, and
Escudero‐Saiz et al. New Hydrophilic Helixone Dialyzers as an Alternative for Hemodialysis Patients With Membrane Hypersensitivity Reactions: A Retrospective Single‐Cohort Study
Silva et al. Cardiovascular Risk Factors: The Old Ones and a Closer Look to the Mineral Metabolism
Ito et al. Aortic Wall Enhancement Detected by Contrast Enhanced CT Scan Predicts Aortic Remodeling After Optimal Medical Treatment.“A New Prognostic Predictor for Acute Uncomplicated Type B Dissection”
Mohamed et al. Decellularization and hope for whole organ bioengineering

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)